cholestyramine resin has been researched along with chloroquine in 3 studies
| Studies (cholestyramine resin) | Trials (cholestyramine resin) | Recent Studies (post-2010) (cholestyramine resin) | Studies (chloroquine) | Trials (chloroquine) | Recent Studies (post-2010) (chloroquine) |
|---|---|---|---|---|---|
| 2,669 | 342 | 190 | 16,405 | 763 | 4,029 |
| Protein | Taxonomy | cholestyramine resin (IC50) | chloroquine (IC50) |
|---|---|---|---|
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | 43 | |
| Spike glycoprotein | Betacoronavirus England 1 | 5.47 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 5.47 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 5.47 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0301 | |
| Amyloid-beta precursor protein | Homo sapiens (human) | 7 | |
| Histidine-rich protein PFHRP-II | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2383 | |
| Procathepsin L | Homo sapiens (human) | 5.47 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 5.47 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Spike glycoprotein | Severe acute respiratory syndrome coronavirus 2 | 3.58 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.375 | |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 1.5 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.27 | |
| Beta-secretase 1 | Homo sapiens (human) | 7 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 2.503 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 6.235 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.02 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gendrel, D; Nardou, M; Richard-Lenoble, D; Verdier, F | 1 |
| Beritić, T; Prpić-Majić, D | 1 |
| Donald, GF; Hunter, GA; Roman, W; Taylor, AE | 1 |
1 review(s) available for cholestyramine resin and chloroquine
| Article | Year |
|---|---|
[Porphyrias].
Topics: Acute Disease; Adenine Nucleotides; Chelating Agents; Chloroquine; Cholestyramine Resin; Chronic Disease; Humans; Porphyrias; Porphyrins; Punctures; Skin Diseases; Veins | 1969 |
2 other study(ies) available for cholestyramine resin and chloroquine
| Article | Year |
|---|---|
[Interaction of cholestyramine and chloroquine].
Topics: Adolescent; Biological Availability; Child; Chloroquine; Cholestyramine Resin; Drug Interactions; Humans | 1990 |
Current concepts of cutaneous porphyria and its treatment with particular reference to the use of sodium calciumedetate.
Topics: Australia; Barbiturates; Chloroquine; Cholestyramine Resin; Diet Therapy; Edetic Acid; Estrogens; Griseofulvin; Humans; Porphyrias; Sulfonamides; Sunburn | 1970 |